Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02955940
Title An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation

Advanced Solid Tumor



Capecitabine + Regorafenib

Capecitabine + Regorafenib + Ruxolitinib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.